# Egeen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/egeen

- Industry: Pharmaceuticals
- Headquarters: Mountain View, US
- Website: www.egeeninc.com
- Total disclosed funding: $4.3M
- Latest round: Series A (Nov 18, 2002)
- Investors on record: 3

## About

Egeen Inc. is a biotechnology company dedicated to advancing health and wellness through innovative diagnostic tools and therapeutic solutions tailored for medical professionals and patients alike.Egeen Inc. specializes in biotechnology, focusing on the development of diagnostic and therapeutic products. Founded by Kalev Kask and based in Mountain View, US, the company has had a consistent business strategy without notable pivots. In January 2008, Egeen Inc. raised USD 0.25 mn in VC funding from Ambient Sound Investments, bringing the total amount raised to USD 0.25 mn from 3 deals. The company's CEO and founder is Kalev Kask, who has a history of leadership in the sector.Egeen International specializes in the development and provision of advanced biotechnological products focused on enhancing health and wellness. Their core offerings include diagnostic tools and therapeutic solutions targeted at oncology and immunology, designed to improve healthcare professionals' ability to assess and treat patients effectively. Egeen serves a diverse client base, including healthcare facilities, research institutions, and pharmaceutical companies across North America and Europe, with an emphasis on clinical use and patient empowerment through self-assessment tools.Egeen International generates revenue through direct sales of its proprietary products to healthcare providers and institutions, alongside strategic partnerships with research organizations and pharmaceutical companies. The company's business model is primarily B2B, with clients placing bulk orders for tailored diagnostic and therapeutic solutions. Pricing plans accommodate various operational scales, enabling access for both large healthcare systems and smaller practices, with contracts outlining product specifications and delivery timelines to foster long-term client relationships.Egeen Inc. plans to utilize the recent funding of USD 0.25 mn raised in January 2008 to support the development of new diagnostic products set for launch in upcoming quarters. The company aims to expand its market reach into Asia and South America by the end of 2024, tapping into emerging healthcare needs. This strategic expansion is part of Egeen's commitment to advancing health solutions globally.

## Funding rounds

- Series A, Nov 18, 2002, $4.3M — ePlanet Capital, SEAF, Biobank Technology Ventures

## Investors

- ePlanet Capital (https://capitalatlas.ai/funds/eplanet-capital) — Series A
- SEAF (https://capitalatlas.ai/funds/seaf) — Series A
- Biobank Technology Ventures — Series A